Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product under development include HQP1351, a BCR-ABL/KIT inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for the treatment of patients with tyrosine kinase inhibitors resistant/refractory GIST. The company also engages in developing APG-2575, an orally administered Bcl-2 selective inhibitor for the treatment of hematologic malignancies with Bcl-2 overexpression, including leukemia, lymphoma, and multiple myeloma; APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of SCLC, lymphoma, and other solid tumors; and APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for the treatment of solid tumors or lymphoma.
In addition, it is involved in the development of APG-1387, a small molecule inhibitor of apoptosis proteins for the treatment of advanced solid tumors and chronic HBV infection; AT-101 for the treatment of chronic lymphocytic leukemia; APG-2449 for non-small-cell lung carcinoma; and HQP8361 for the treatment of cancer. Ascentage Pharma Group International has a clinical collaboration with Acerta Pharma to evaluate the combination of Bcl-2 and BTK inhibitors in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; and MSD to evaluate the combination of APG-115 and KEYTRUDA for the treatment of patients with advanced solid tumors. It has cooperative research and development agreement (CRADA) with the National Cancer Institute.
The company was founded in 2009 and is headquartered in Suzhou, China.